How Much Does an Implanted Defibrillator Cost?

An implantable cardioverter-defibrillator (ICD) typically costs between about $25,000 and $50,000 for the initial device and implantation procedure in the United States, though the total can swing widely depending on the type of device, whether the surgery happens as an inpatient or outpatient procedure, and how the hospital bills. That sticker price, however, is just the beginning. The lifetime expense of living with an ICD includes years of follow-up visits, potential lead revisions, battery replacements, and the occasional complication that can dwarf the original implant bill.

What the Initial Implant Actually Costs

The device itself accounts for the largest single chunk of the bill. ICD pulse generators are sophisticated pieces of hardware containing processors, capacitors, a lithium battery, and (in most models) one or more electrode leads threaded into the heart. Hospitals purchase them from manufacturers, and the markup between wholesale and what appears on your bill can vary enormously by institution. In a cost analysis at a U.S. academic medical center, the mean total cost of an ICD implant, covering the device, the procedure, and the surrounding hospital stay, came to roughly $33,500 for inpatient implants and about $28,000 for outpatient implants.¹ Those figures are from a cost-based analysis, meaning they attempt to reflect what the hospital actually spent rather than what it charged. The billed amount, which is what an uninsured patient might see, ran higher still: about $35,600 on average using charge-to-cost ratios at the same center.¹

For elderly patients receiving ICDs for primary prevention, the costs look even steeper when you account for the surrounding hospitalization. One study of Medicare beneficiaries found that ICD patients had higher median hospital costs of about $41,500 above non-ICD patients in the first 30 days after their initial hospitalization, and that gap persisted at the one-year mark.² The outpatient and physician costs added roughly another $1,800 at six months.²

How the Type of Device Changes the Price

Not all ICDs are built the same way, and the differences have real financial consequences. The traditional design, a transvenous ICD (TV-ICD), threads one or more leads through a vein directly into the heart chambers. The newer subcutaneous ICD (S-ICD) places the lead just under the skin along the breastbone, avoiding the veins and heart entirely. That matters because lead complications, including infections, fractures, and dislodgements, are one of the most expensive problems in ICD care. In a UK propensity-matched study, the total mean cost per patient, including complication-related expenses, was about $13,600 for the transvenous device and roughly $17,200 for the subcutaneous model.³

The S-ICD hardware is more expensive upfront, which accounts for most of that price gap. But the trade-off is intriguing: the subcutaneous device was associated with a 70% lower risk of device-related complications compared to transvenous models in that same study.³ That reduction in complications could narrow or even reverse the cost gap over longer follow-up periods, since each complication requiring hospital care adds thousands to the lifetime bill. For younger patients who will need the device for decades and may face multiple lead revisions, the upfront premium for an S-ICD can start to look like a bargain.

There is also a meaningful cost difference between single-chamber ICDs and cardiac resynchronization therapy defibrillators (CRT-Ds), which combine defibrillation with a pacing function designed to improve the coordination of the heart’s pumping. CRT-D devices cost more and involve a more complex procedure with an additional lead. A large French cohort study of over 19,000 patients found that receiving a CRT-D instead of a single-chamber ICD increased the total ICD-related cost per patient by about 20%.⁴

Inpatient Versus Outpatient Implantation

Where and how the implant is performed has a surprisingly large effect on the final bill. The shift toward outpatient ICD implantation in electrophysiology labs, rather than operating rooms with multi-day hospital stays, has been one of the biggest drivers of cost reduction over the past two decades. An early study comparing the same generator-replacement procedure done in an operating room versus an outpatient electrophysiology lab found that total charges (excluding the device itself) dropped from about $9,400 to roughly $4,500 when performed outpatient, a reduction of more than half. Physician fees, hospital charges, and inpatient days all fell significantly.⁵

Today, most new ICD implants in the U.S. are done as same-day or one-night-stay procedures unless the patient’s condition demands otherwise. But the cost-saving potential still depends on local hospital policies, insurance negotiations, and whether complications arise during or after the procedure. Patients who develop post-surgical issues like pocket hematoma or lead dislodgement may end up with an inpatient-level bill regardless of the original plan.

The Long Tail of Follow-Up and Replacement Costs

An ICD is not a one-time purchase. The battery in most devices lasts five to ten years, depending on how often it delivers therapy. When the battery nears depletion, the entire pulse generator must be surgically swapped out. The French cohort study found that patients who needed a device replacement saw their total ICD-related cost increase by about 71% compared to those who did not.⁴ For someone who receives their first ICD at age 50, that could mean three or four generator changes over a lifetime, each carrying its own procedural risk and bill.

Between replacements, patients typically visit a device clinic every three to six months for routine interrogation, where a technician downloads stored data from the ICD to check battery status, lead integrity, and any recorded heart rhythm events. These visits add up, both in direct cost and in time off work, transportation, and co-pays. Remote monitoring technology, which lets the ICD transmit data to the clinic over a wireless connection, has been shown to cut those expenses meaningfully. One European study found that substituting two routine in-office visits per year with remote check-ins reduced the overall cost of routine ICD follow-up by about 40% per patient.⁶ A randomized trial (the ECOST study) found that non-hospital care costs for device management were 26% lower in the remote-monitoring group, saving about €74 per patient per year, with the savings growing over time to a 36% reduction in the final year of follow-up.⁷

Remote monitoring is now standard practice at many centers, but it does not eliminate in-person visits entirely. Most guidelines still call for at least one annual in-person check, and any detected abnormality during a remote transmission usually triggers an office visit or procedure.

When Complications Drive Costs Through the Roof

The most expensive thing that can happen to an ICD patient, short of the cardiac event the device is meant to prevent, is a device infection. Infected leads or generator pockets usually require complete system extraction, a technically demanding surgery, followed by intravenous antibiotics and eventually reimplantation of a new system. A study using U.S. hospital data found that the mean hospital cost for managing a cardiac device infection was roughly $55,500, while the mean out-of-pocket cost to patients on Medicare fee-for-service was about $2,150.⁸ Hospitals themselves often lost money on these cases, with average margins of negative $30,800 per Medicare fee-for-service infection case.⁸

Australian data paints an even grimmer picture. Among patients who required complete system removal and reimplantation due to infection, the cost reached about $128,900 for ICD patients and nearly $148,900 for those with CRT-defibrillator systems.⁹ These figures include the full episode of care, from the extraction surgery through extended hospital stays and the new device. The risk of infection rises with each subsequent procedure, which means generator replacements are not just costly in themselves but compound the odds of a devastating complication later.

Who Actually Pays and How Much

In the U.S., Medicare covers ICDs for approved indications, which includes most primary and secondary prevention scenarios supported by clinical trial evidence. Medicare’s coverage has been a key driver of ICD adoption since the Centers for Medicare and Medicaid Services expanded their coverage criteria in the mid-2000s. Under traditional Medicare, the patient’s share is limited to hospital deductibles and coinsurance, plus Part B copays for outpatient follow-up. As noted in the infection-cost study, out-of-pocket costs for Medicare beneficiaries averaged around $1,650 to $2,150 depending on the plan type, even during the expensive complication of a device infection.⁸

Private insurance generally covers ICDs as well, though out-of-pocket costs vary with plan design. High-deductible plans may leave the patient responsible for several thousand dollars of the initial procedure. Prior authorization is almost always required, and some insurers will push back on primary prevention implants in patient populations where the cost-effectiveness data is less clear-cut.

Outside the U.S., coverage frameworks differ dramatically. In Brazil, a cost-effectiveness analysis found that the incremental expense of ICD therapy over pharmaceutical treatment was about R$62,700 (roughly $12,500 at the time) from the public-sector perspective and R$83,900 from the private insurance perspective.¹⁰ The cost-effectiveness ratio per quality-adjusted life-year gained was considerably less favorable in the private insurance scenario.¹⁰ In countries with national health systems, access often depends on whether the device meets the system’s cost-effectiveness threshold, and wait times can be significant.

The Cost-Effectiveness Debate

Whether an ICD is “worth the money” depends heavily on who receives it. The landmark cost-effectiveness analysis published in the New England Journal of Medicine, drawing on data from six major trials, found that ICDs added between about one and three quality-adjusted life-years per patient and between $68,300 and $101,500 in costs. The resulting cost-effectiveness ratio ranged from about $34,000 to $70,200 per quality-adjusted life-year gained, numbers that fall within the range most health economists consider acceptable in the U.S.¹¹

But those are averages across trial populations, and the picture gets murkier in specific groups. In the MADIT-II trial, which enrolled patients with prior heart attacks and reduced heart function, the average survival gain from the ICD was only about two months over 3.5 years, while the additional cost was $39,200. The resulting cost-effectiveness ratio was $235,000 per year-of-life saved over the trial period, though longer projections out to 12 years brought it down to a range of $78,600 to $114,000.¹² The message here is that the device pays for itself in survival terms only if it keeps working for many years. For a 45-year-old with decades of life ahead, the math is more favorable than for an 80-year-old with multiple serious health conditions.

An Iranian analysis offers a perspective from a middle-income country, where the same economic equation plays out differently. Lifetime ICD costs were estimated at about $41,100 per patient compared to roughly $8,600 for drug therapy, yielding an incremental cost-effectiveness ratio of about $24,300 per quality-adjusted life-year. Despite the seemingly reasonable number by U.S. standards, the authors concluded this was not cost-effective for Iran given the country’s willingness-to-pay threshold.¹³ A Canadian trial-based analysis found mean costs of about C$87,700 per ICD patient over 6.3 years (compared to C$38,600 for patients treated with medication), with cost-effectiveness improving substantially in patients who had the weakest heart function.¹⁴

Factors That Push Your Personal Cost Higher or Lower

Several variables determine where an individual patient falls on the cost spectrum. Age is one of the most significant. The French national database study found that patients under 55 had total ICD-related costs roughly 20% higher than those over 75, primarily because younger patients live long enough to need more replacements and accumulate more follow-up visits.⁴ Patients being treated for high blood pressure also carried about 20% higher costs, likely reflecting the broader burden of cardiovascular disease management.⁴

Other factors are harder to predict. Whether you develop a complication is partly a matter of luck, though certain risk factors like diabetes, kidney disease, and having had previous cardiac device procedures increase the odds of infection and lead failure. The choice of implanting hospital matters too. High-volume centers tend to have lower complication rates, and teaching hospitals may charge differently than community hospitals for the same procedure.

Your insurance plan design has an outsized effect on your personal out-of-pocket exposure. A patient with a $3,000 deductible and 20% coinsurance on a $40,000 procedure faces a very different bill than someone with a $500 deductible and 10% coinsurance capped at $5,000. Many patients hit their annual out-of-pocket maximum with the initial implant alone, which means subsequent costs that calendar year, like follow-up visits and cardiac rehabilitation, are covered at 100%.

ICD Deactivation and End-of-Life Considerations

One cost that rarely appears in the financial literature but weighs heavily on patients and families involves end-of-life care. An ICD does not know when a patient is dying of something else. If a terminally ill patient’s heart develops a fatal rhythm, the device will shock it, potentially repeatedly, in an attempt to restore a normal beat. These shocks are painful and distressing, and they can interfere with a peaceful death.

Deactivating the shocking function of an ICD is straightforward from a technical standpoint: a technician places a programmer over the device and turns off the tachyarrhythmia therapies. The pacing function can be left on if desired. The procedure costs very little and can be done at the bedside. The challenge is not technical but logistical and emotional. Studies have found that communication about deactivation often happens too late or not at all, leaving patients and families unprepared.¹⁵ The ethical framework supporting deactivation is well established: patients have the right to refuse or withdraw any medical treatment, including ICD therapy.¹⁶ Yet implementation remains patchy. Patients entering hospice with an active ICD may receive shocks during their final hours because no one arranged the deactivation in time. The human cost of that failure is hard to quantify but real.

Advocates in palliative cardiology have called for routine advance-care planning conversations at the time of implant, not just at the end of life, so patients understand from the beginning that the device can be turned off when its burdens outweigh its benefits.¹⁵ For patients and families facing this decision, the financial cost of deactivation is negligible. The cost of not having the conversation, however, can be enormous in ways that do not show up on a hospital bill.

1
PubMed Central. Implantable cardioverter defibrillator practices and costs at an academic medical center
2
PubMed. Outcomes and costs of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death among the elderly
3
PubMed. A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator
4
PubMed. Healthcare costs in implantable cardioverter-defibrillator recipients: A real-life cohort study on 19,408 patients from the French national healthcare database
5
Pacing and Clinical Electrophysiology. Replacing Abdominally Implanted Defibrillators: Effect of Procedure Setting on Cost
6
PubMed Central. Remote monitoring of implantable cardioverter defibrillator patients: a safe, time-saving, and cost-effective means for follow-up
7
EP Europace. Costs of remote monitoring vs. ambulatory follow-ups of implanted cardioverter defibrillators in the randomized ECOST study
8
Circulation: Arrhythmia and Electrophysiology. Impact of Cardiac Implantable Electronic Device Infection
9
Journal of Arrhythmia. Economic Burden Associated With Cardiac Implantable Electronic Device (CIED) Infections in New South Wales, Australia: A Population‐Based Study Using Linked Administrative Data
10
SciELO / Arquivos Brasileiros de Cardiologia. Cost-effectiveness of implantable cardioverter defibrillators in Brazil in the public and private sectors
11
PubMed. Cost-effectiveness of implantable cardioverter-defibrillators
12
Journal of the American College of Cardiology. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II
13
PubMed Central. Cost-effectiveness analysis of an implantable cardiac defibrillator compared with pharmaceutical therapy in patients hospitalized with arrhythmia in Iran
14
Circulation. Cost-Effectiveness of the Implantable Cardioverter-Defibrillator
15
Trends in Cardiovascular Medicine. The implantable cardioverter-defibrillators at the end of life: a double-edged sword of a life-saving technology
16
PubMed Central. Management of Implantable Defibrillators in Hospice